Danaher Stock Forecast for 2022 - 2025 - 2030
Updated on 12/02/2022
Danaher Stock Forecast and Price Target
The average target price for Danaher's stock set by seven renowned analysts in recent months is $315.00, representing a potential upside of approximately 14.74% from its last closing price if met by 2023. This estimation is based on a high estimate of $342.00 and a low estimate of $242.00. Although you may not be interested in DHR stock, you should still be aware of its competitors.
14.74% Upside
Danaher Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's Price has grown, moving from $136.32 to $303.11 – an increase of 122.35%. In the next year, analysts predict that Fair Value will jump to $313.97 – up 3.58% from the current level. Looking ahead to nine years, experts forecast that Fair Value will grow by 45.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AVGO Stock Forecast | Broadcom | Buy |
17
|
$550.75 | $649.33 | 18.02% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$107.93 | $128.88 | 5.62% |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$80.88 | $79.05 | 2.50% |
| AMGN Stock Forecast | Amgen | Hold |
7
|
$285.94 | $246.51 | -9.77% |
| GE Stock Forecast | General Electric | Outperform |
17
|
$85.26 | $94.11 | 5.56% |
Danaher Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's Revenue has grown, moving from $17.05B to $29.45B – an increase of 72.76%. In the next year, analysts predict that Revenue will jump to $30.82B – up 4.65% from the current level. Looking ahead to nine years, experts forecast that Revenue will grow by 30.54%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$250.83 | $272.08 | 8.04% |
| MMM Stock Forecast | 3M | Hold |
16
|
$125.99 | $147.79 | 1.20% |
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$46.12 | $49.85 | 5.16% |
Danaher Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's Dividend per Share has seen an increase, rising from $0.64 to $0.84. This represents a growth of 31.25%. Analysts predict that Danaher's Dividend per Share will increase in the upcoming year, reaching $1.05. This would represent an increase of 25.00%. Over the next nine years, experts predict that Danaher's Dividend per Share will grow at a rate of 92.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ETN Stock Forecast | Eaton | Outperform |
16
|
$163.36 | $162.20 | 4.68% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
55.03€ | 67.79€ | 43.56% |
| F Stock Forecast | Ford Motor | Hold |
13
|
$14.08 | $15.43 | -0.57% |
Danaher Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Free Cash Flow for Danaher has grown by 109.84%, going from $3.37B to $7.06B. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $7.55B – an increase of 6.92%. Over the next nine years, experts anticipate that Free Cash Flow growth for Danaher will be 40.01%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| EMR Stock Forecast | Emerson Electric | Outperform |
10
|
$95.64 | $102.14 | 8.74% |
| 6501 Stock Forecast | Hitachi | Buy |
18
|
¥7.32k | ¥0.00 | 16.09% |
| EW Stock Forecast | Edwards Lifesciences | Outperform |
15
|
$77.56 | $127.85 | 22.49% |
Danaher Net Income Forecast for 2022 - 2025 - 2030
Danaher's Net Income has seen growth In the last three years, going from $2.65B to $6.43B – a gain of 142.67% In the next year, analysts believe that Net Income will reach $7.70B – an increase of 19.74%. For the next nine years, the forecast is forNet Income to grow by 47.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$156.12 | $157.63 | 3.77% |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$301.85 | $242.78 | 7.67% |
| ECL Stock Forecast | Ecolab | Outperform |
18
|
$151.94 | $179.10 | 4.98% |
Danaher EBITDA Forecast for 2022 - 2025 - 2030
Danaher's EBITDA has grown in the last three years, jumping from $4.27B to $10.34B – an increase of 142.21%. In the next year, analysts predict that EBITDA will reach $10.68B – an increase of 3.37%. For the next nine years, the forecast is for EBITDA to grow by 25.57%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| DOW Stock Forecast | Dow | Hold |
11
|
$51.07 | $73.11 | -6.01% |
| AME Stock Forecast | AMETEK | Outperform |
17
|
$143.29 | $156.00 | 3.81% |
| GLW Stock Forecast | Corning | Outperform |
17
|
$34.24 | $42.00 | 6.02% |
Danaher EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's EBIT has increased by 164.37%, going from $3.09B to $8.17B. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $8.30B – an increase of 1.63%. The Danaher forecast is for EBIT to reach $10.36B or grow by 26.83%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CERN Stock Forecast | Cerner | - |
13
|
$94.92 | $93.31 | 13.03% |
| DOV Stock Forecast | Dover | Outperform |
18
|
$142.49 | $158.40 | -1.75% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$76.99 | $77.25 | -1.29% |
Danaher EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Danaher's EPS has grown, moving from $4.52 to $10.05 – an increase of 122.35%. In the next year, analysts predict that EPS will jump to $10.41 – up 3.58% from the current level. Looking ahead to nine years, experts forecast that EPS will grow by 45.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
68.36€ | 0.00€ | 53.60% |
| CSL Stock Forecast | Carlisle Companies | Outperform |
18
|
$262.10 | $332.50 | 33.54% |
| AFX Stock Forecast | Carl Zeiss Meditec | Outperform |
18
|
133.05€ | 165.40€ | 11.99% |